RT Journal Article
SR Electronic
T1 Assessing the effect of social contact structure on the impact of pneumococcal conjugate vaccines
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.08.13.24311931
DO 10.1101/2024.08.13.24311931
A1 Wong, Anabelle
A1 Kramer, Sarah C.
A1 Weinberger, Daniel M.
A1 Domenech de Cellès, Matthieu
YR 2024
UL http://medrxiv.org/content/early/2024/08/20/2024.08.13.24311931.abstract
AB Although pneumococcal conjugate vaccines (PCVs) have greatly reduced the incidence of invasive diseases caused by vaccine-targeted serotypes (VT) of Streptococcus pneumoniae, vaccine impact may be eroded by the increase in rates of disease caused by non-vaccine serotypes (NVT) – a phenomenon known as serotype replacement. Here, we investigated the effect of social contact patterns on the dynamics of vaccine impact and serotype replacement in carriage.We developed a neutral, age-structured, susceptible–colonized (S–C) model incorporating VT-NVT co-colonization and childhood immunization with PCVs and verified it against real-world carriage data. Using empirically derived contact matrices from 34 countries, we assessed the impact of contact patterns of different age groups on the time-to-elimination, here defined as the time taken for the proportion of VT among circulating serotypes to drop to 5% of the pre-PCV level. Finally, we quantified the contribution of various parameters—such as vaccine efficacy, coverage, immunity waning, and population susceptibility—to the dynamics of VT elimination.Our model recapitulated the observed prevalence of carriage of VTs observed in the real-world data and showed that varying the contact structure alone led to different time-to-elimination (range: 3.8 – 6 years). We found that higher total contact rate and assortativity in children under 5 were key factors in accelerating VT elimination. In addition, higher vaccine efficacy and coverage, and slower immunity waning led to shorter time-to-elimination.These findings illuminate the mechanisms controlling the dynamics of vaccine impact and serotype replacement and may help predict the impact of the higher-valency PCVs in communities with different contact patterns.Competing Interest StatementD.M.W. received consulting fees from Pfizer, Merck, GSK, Affinivax, and Matrivax for work unrelated to this manuscript and is the principal investigator on research grants from Pfizer and Merck on work unrelated to this manuscript. M.D.d.C. received postdoctoral funding (2017-2019) from Pfizer and consulting fees from G.S.K. for work unrelated to this manuscript. All other authors declare no conflicts of interest.Funding StatementThis study did not receive any funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study used only openly available human contact data that were originally located at: https://github.com/mobs-lab/mixing-patternsI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe code and data are available online at Edmond, the Open Data Repository from the Max Planck Society. https://doi.org/10.17617/3.RIGYAK